Introduction
Restenosis, caused by neointimal formation, is a common adverse effect of percutaneous vascular interventions, such as balloon angioplasty and stent implantation for coronary and peripheral artery diseases. Restenosis is the result of inflammatory cell infiltration followed by vascular smooth muscle cell (VSMC) migration and proliferation at the site of vascular intervention. 1 -3 However, the prevention of restenosis using anti-inflammatory drugs has proven unsatisfactory in many clinical trials. 4 -7 Therefore, understanding the migration and proliferation of VSMCs during neointimal formation may be beneficial in identifying novel molecular targets, and thereby in reducing the frequency and severity of restenosis.
Extracellular Ca 2+ influx is known to trigger cell-cycle progression and cell proliferation in many cell types including VSMCs. 8 In rat
VSMCs, a coordinated elevation of the intracellular Ca 2+ concentration ([Ca 2+ ] i ) is required for insulin-like growth factor-1 (IGF-1)-dependent G 1 -to S-phase cell-cycle progression. 9 In VSMCs, extracellular Ca 2+ entry is mainly through two types of voltage-gated Ca 2+ channels, L-type (L-channels) and T-type (T-channels). Moreover, L-and T-channels are believed to contribute to the specificity of the diverse effects of Ca 2+ . 10, 11 For example, Ca 2+ influx via L-channels is required for smooth muscle contraction, and L-channel blockers are clinically used to lower blood pressure in hypertensive patients. 12 On the other hand, in rat VSMCs, T-channels are predominantly expressed in the G 1 and S phases, but not in the G 0
phase. This indicates a putative role of T-channels in the regulation of cell-cycle progression and cell proliferation. 13 Two types of T-channels, Ca v 3.1 and Ca v 3.2, are expressed in the cardiovascular system. 14, 15 It has been shown that knock down or blockade of Ca v 3.1 inhibits cell proliferation of human pulmonary artery smooth muscle cells (PASMCs) in vitro. 16 In addition, Ca v 3.1 has also been found to be the predominant T-channel that promotes oxygenation-induced closure of the rat ductus arteriosus in VSMCs. 17 Recently, Ca v 3.1 has been shown to be the primary entry for Ca 2+ influx involved in the IGF-1-induced cell proliferation of rat PASMCs. 18 However, the involvement of Ca v 3.2 in VSMC proliferation has not yet been demonstrated. Recent clinical trials have found that calcium channel blockers (CCBs) are probably effective in the reduction of restenosis and related clinical events after percutaneous coronary interventions (PCI). 19 -22 Although the currently available CCBs are mostly aimed at blocking L-channels, most of them can also partially block T-channels. 23 For example, verapamil, an L-channel blocker, is able to improve long-term clinical outcomes of native coronary arteries after PCI by reducing the rate of high-grade restenosis. 21 Verapamil also exhibits the potency to partially block T-channels. 24 Furthermore, mibefradil, an L-and T-channel blocker, has a stronger antiproliferative effect on VSMCs both in vitro and in vivo. 25 
Methods

Animals
All research conformed to the National Institutes of Health and Institutional Animal Care guidelines, and also those of the Utilization Committee, Academia Sinica (Taipei, Taiwan). Ca v 3.1 2/2 and Ca v 3.2 2/2 mice were generated and genotyped as described previously.
26,27
2.2 Carotid artery injury operation, tissue harvesting, and processing
Eight to 10-week-old adult male C57BL/6 mice (n ¼ 7 each group) were anesthetized (vaporized 1% isoflurane) and received right common carotid artery injury by inserting and removing a 0.014-in. guide wire (1003315H, Abbott Vascular Inc.) three times. A typical operation procedure took ,30 min. BrdU (50 mg/kg, B5002, Sigma) was injected intraperitoneally on Day 10, Day 11, Day 12, and Day 13 after artery injury. Two weeks after artery injury, the mice were anesthetized and perfused transcardially with phosphate buffer saline (PBS), followed by 10% neutral buffered formalin solution. Both the right and left carotid arteries were harvested and the left carotid arteries were used as negative controls. For cryosections, the mice received only PBS perfusion. The bilateral carotid arteries were isolated separately, fixed in tissue freezing medium and stored at 2808C.
Histological, immunohistochemical, and immunofluorescent analyses
Four cross-sections (5 mm thickness, 400-500 mm apart) of the injured arteries were taken for histomorphological analysis. Digitized images of the H & E and elastic stains (Elastic Stain Kit, HT25A, Sigma) were analyzed using Image-Pro Plus 6.0 (Media Cybernetics, USA) to calculate the intimal area to the medial area ratio (I/M). Immunohistochemical stains for endothelium, VSMCs, pan-leucocytes, and the proliferative cells were conducted using anti-von Willebrand factor (vWF) antibody (1:200, A0082, Dako), anti-smooth muscle a-actin (1:3000, A5228, Sigma), anti-mouse CD45 (1:100, 550539, BD Pharmingen), and anti-BrdU antibodies (1:400, Clone BU-33, Sigma), respectively. Total cell nuclei were stained using 4 ′ ,6-diamidino-2-phenylindole (DAPI, 5 mmol/L in PBS, 32670, Sigma). Vascular injury was judged by the loss or disruption of endothelial cells and loosening of media. The degree of vascular injury was quantified using the ratio of total injured length to vascular inner circumference. Proliferation indices were calculated as BrdUpositive cell number/total DAPI-positive cell number in neointima and media. Anti-Ca v 3.1 (1:100, ACC-021, Alomone) and anti-a-actin antibodies (1:1000, A5228, Sigma) were used for immunofluorescent staining of the cryosections of mouse carotid arteries.
VSMC cultures and proliferation assays
Mouse and rat thoracic aortic VSMCs were isolated and cultured as described previously. 28, 29 The first passage of mouse VSMCs and passages 3-8 of rat VSMCs were used in our study. VSMCs were starved for 48 h before 10% foetal bovine serum (FBS) stimulation. For cell proliferation assay, cells were seeded at a density of 1500 cells/cm 2 . The cell proliferation rate was measured using a CyQUANT proliferation assay (C35007, Invitrogen) according to the manufacturer's instructions. In some experiments, the cells were counted using a hemocytometer to validate the results of the CyQUANT proliferation assay. Calmodulin agonist, CALP1 (10 mmol/L, 2090, Tocris) was added 1 day after 10% FBS stimulation. T-type Ca 2+ channel blocker, NNC55-0396 (5 mmol/L, 2268, Tocris) was added at the same time as 10% FBS stimulation. 0.9% saline was used as the control.
Cell-cycle analysis by propidium iodide staining and flow cytometry
Trypsinized VSMCs were resuspended in PBS (1×10 6 cells/mL) and fixed with cold 70% ethanol at 48C for at least 1 h. After fixation, the cells were resuspended in 1 mL propidium iodide (PI) solution (40 mg/mL PI, 0.1 mg/ mL RNase A, 0.05% Triton X-100 in 1 mL PBS) in the dark at 378C for 40 min. The cells were washed and resuspended in PBS for flow analysis using a BD FACS Canto flow cytometer (BD Biosciences). We used FlowJo Windows version 7.6 (Tree Star) for the cell-cycle analysis.
Leucocyte recruitment and functional assays
A thioglycollate-induced peritonitis model was used to obtain leucocytes from the peritoneal cavity of wild-type and Ca v 3.1 2/2 mice. Cultured leucocytes were stimulated with lipopolysaccharide (LPS, 10 mg/mL) for 24 h. The culture media were collected and the amounts of TNF-a and IL-1b were determined using commercial ELISA kits.
Reverse transcription and real-time quantitative polymerase chain reaction
Total RNA was extracted from homogenized lysates of the carotid arteries, leucocytes, and cultured VSMCs using Trizol reagent (Invitrogen) according to the manufacturer's protocols. The RNA from four arteries was pooled together for one set of TaqMan RT-qPCR experiments. The primers and probes used for detecting mouse and rat Ca v 3.1 and GAPDH are listed in the Supplementary material online. Because the expression of T-channels is cell-cycle dependent, we used double thymidine block to synchronize the rat VSMCs at the G 1 /S boundary for the detection of Ca v 3.1.
Western blot
Equal loading of 30 mg protein extracts from rat VSMCs at different time points after 10% FBS stimulation were separated by 12% SDS-PAGE for western blot. Anti-cyclin E1 antibody (1:500, GTX27959, GeneTex) was used for immunoblotting of cyclin E and anti-GAPDH antibody (1:5000, NB300-221, Novus Biologicals) for the housekeeping protein.
Lentiviral shRNA production and transduction
Lentiviral shRNA was obtained from the National RNAi Core Facility Platform of Academia Sinica, Taiwan. The methods for the production and transduction are provided at the following website (http://rnai.genmed. sinica.edu.tw/index). The shRNA sequences for Cacna1g (shCav3.1) and luciferase (shLuc) are listed in the Supplementary material online. Rat VSMCs (2×10 4 cells/well) were transfected with lentiviral particles (MOI ¼ 5) using a spinning infection method. Puromycin (2.5 mg/mL, P8833, Sigma) was used to select lentivirus-infected cells.
NNC55-0396 dihydrochloride infusion
NNC55-0396 dihydrochloride was dissolved in 0.9% saline. NNC55-0396 (1 mg) was delivered subcutaneously for 1 week using an osmotic minipump (ALZET, model 1007D, Durect) implanted after the carotid injury. Saline was used as the control.
Statistics
Data are presented as mean + SEM. Statistical comparisons were performed using independent-samples t-tests for two sample groups, one-way ANOVA for three sample groups, or repeated measures ANOVA for the proliferation assay. Dunnett's t-test was used for the post-hoc analysis with the wild-type group as the controls. A P-value of ,0.05 was considered statistically significant. were used for further analysis. We next determined whether VSMCs are the major cell type responsible for the increased neointima region. Injured arteries were stained with a-actin antibody and the results showed that VSMCs were the predominant cell type in the neointima ( Figure 1A) . To ensure the consistency of arterial injury during surgery, H & E staining and vWF (an endothelium marker) immunohistochemical staining were performed 24 h after the wire injury ( Figure 1C) . Quantitative results showed that the degree of carotid artery injury was similar between wild-type and Ca v 3.1 2/2 mice ( Figure 1D ).
Results
Impaired neointimal formation
Previous studies have shown that after artery injury, a reduced inflammation response, and especially reduced leucocyte recruitment, can lead to the reduction of neointimal formation. 30, 31 To clarify whether the reduced neointimal formation observed in Ca v 3.1 2/2 mice was due to reduced leucocyte recruitment, we examined leucocyte recruitment by staining the injured arteries with anti-CD45 antibody, a panleucocyte marker, 7 days after the wire injury ( Figure 1E ). As shown in Figure 1E , Figure S1 ). The responses of leucocytes to LPS stimulation were then measured. The results showed that the quantities of TNF-a and IL1b released after LPS treatment were similar in both wildtype and Ca v 3.1 2/2 leucocytes (see Supplementary material online, Figure S2 ). These results suggest that the observed reduction of neointimal formation in Ca v 3.1 2/2 mice was not caused by reduced leucocyte recruitment or altered leucocyte function.
We then used BrdU labelling to investigate the correlation between defective smooth muscle proliferation and reduced neointimal formation in Ca v 3.1 2/2 mice. The results showed that in wild-type mice, the majority of the BrdU-positive cells were localized in the neointima of the injured arteries ( Figure 2A) . In contrast, in Ca v 3.1 2/2 mice, the quantity of BrdU-positive cells was significantly reduced, and they were mainly localized in the media. Furthermore, the neointimal cell proliferation index was significantly lower in Ca v 3.1 2/2 injured arteries than in wild-type controls ( Figure 2B ). These results suggest that the reduced neointimal formation in Ca v 3.1 2/2 mice after artery injury may be caused by defects in smooth muscle proliferation.
3. Figure 3A) . Ca v 3.1 mRNA was upregulated 1 week after wire injury when there was no detectable neointimal formation ( Figure 3A , left panel inset), suggesting that Ca v 3.1 is crucial for neointimal formation. Immunofluorescent staining with anti-Ca v 3.1 antibodies also showed a dramatic increase of Ca v 3.1 in the neointima of the injured arteries 2 weeks after wire injury in wild-type mice, whereas there was no detectable signal in the wild-type control or Ca v 3.1 2/2 arteries ( Figure 3B ). Cav3.1 is required for neointimal formation
Deficiency of Ca v 3.1 reduced VSMC proliferation
To confirm that a loss of Ca v 3.1 impairs VSMC proliferation, we compared the growth curve of isolated aorta VSMCs from wild-type and Ca v 3.1 2/2 mice ( Figure 4A ). Our results showed that the proliferation rate of Ca v 3.1 2/2 VSMCs was significantly lower compared with that of wild-type VSMCs. Due to the low amount of isolated mouse VSMCs, we used rat aorta VSMCs as our in vitro cell model to study the signalling pathway triggered by the Ca 2+ influx via Ca v 3.1.
Using an RNAi technique, we first showed that shCa v 3.1 repressed the level of Ca v 3.1 mRNA to 35% compared with the untreated controls ( Figure 4B ), whereas shLuc had no effect on the Ca v 3.1 mRNA level. Similar to the proliferation rate in Ca v 3.1 2/2 VSMCs, the proliferation rate in Ca v 3.1 knock down rat VSMCs was also reduced ( Figure 4C) . Previous studies have shown that T-channels are predominantly expressed in the G 1 and S phases but not in the G 0 phase, 13 so a reduced level of Ca v 3.1 may affect cell-cycle progression. To validate this hypothesis, we detected the levels of cyclin E during cell proliferation in the shLuc-and shCa v 3.1-treated rat VSMCs. Cyclin E, an activator of Cdk2, is tightly regulated during cell-cycle progression, and its expression level peaks at the G 1 /S phase boundary followed by a rapid decline during the S phase. 33 -35 From PI flow cytometry results, we found that wild-type VSMCs progressed into the S phase at about 24 h after 10% FBS stimulation, whereas shCa v 3.1-treated VSMCs displayed a delayed S-phase progression (see Supplementary material online, Figure S3 ). We next established a time course experiment to detect the dynamics of cyclin E levels from 16 to 28 h after serum stimulation in shLuc-and shCa v 3.1-treated VSMCs. Our results showed that in shLuc-treated VSMCs, the level of cyclin E peaked at 20 h and declined at 24 h. In contrast, in shCa v 3.1-treated VSMCs, the cyclin E level remained relatively constant throughout the time course ( Figure 4D ). The ratio of the cyclin E levels between 20 and 24 h in the shLuc-treated VSMCs was significantly higher than that of the shCa v 3.1-treated VSMCs ( Figure 4E ). These results suggest that a deficiency or knock down of Ca v 3.1 may reduce VSMC proliferation by delaying the G 1 /S transition, and that Ca v 3.1 plays a role in cyclin E signalling.
Calmodulin agonist CALP1 increased cell proliferation in Ca v 3.1 knockdown VSMCs
It has been shown that CaM-dependent cyclin E/Cdk2 activity is required for the Ca 2+ -sensitive G 1 /S phase transition in VSMCs. 36, 37 However, the source of Ca 2+ which activates this signalling pathway is unclear. We hypothesized that the Ca 2+ influx via Ca v 3.1 activates the Ca 2+ /CaM pathway to promote the G 1 -to-S phase transition in VSMCs. To verify our hypothesis, we treated VSMCs with CALP1, a cell-permeable CaM agonist that binds to the EF hands of CaM. 38 We found that CALP1 (10 mmol/ L) enhanced cell proliferation in the shCa v 3.1-treated VSMCs ( Figure 5 ), but it had no effect on the proliferation rate of the wildtype and shLuc-treated VSMCs. These results suggest that in VSMCs, an enhanced CaM activity can partially rescue the impaired cell proliferation caused by Ca v 3.1 deficiency.
NNC55-0396 dihydrochloride, a selective T-channel blocker, inhibited neointimal formation
Having demonstrated that Ca v 3.1 was involved in the VSMC proliferation during neointimal formation after artery injury, we explored the possibility of using T-channel blockers as a therapeutic tool to Figure 5 Calmodulin agonist CALP1 increased cell proliferation in Ca v 3.1 knockdown VSMCs. CALP1 (10 mmol/L) had no effect on the cell proliferation rate of wild-type (A) and shLuc-treated (B) VSMCs. (C) CALP1 (10 mmol/L) increased the cell proliferation rate of shCa v 3.1-treated VSMCs. The cell proliferation rate was measured using a CyQUANT cell proliferation assay. n ¼ 4 for each group. ***P , 0.001, compared with the shCa v 3.1-treated group. Elastic staining of injured carotid arteries from saline-and NNC55-0396-treated wild-type mice subjected to wire injury for 2 weeks. Saline (0.9%) or NNC55-0396 (1 mg) was delivered subcutaneously by an osmotic minipump after artery injury for 1 week. (C) NNC55-0396 treatment reduced the intima/media (I/M) ratio of wild-type carotid arteries that were injured for 2 weeks. The I/M ratios of salineand NNC55-0396-treated groups were 0.635 + 0.163 (n ¼ 5) and 0.198 + 0.100 (n ¼ 6), respectively. *P ¼ 0.042, compared with the saline-treated group.
Cav3.1 is required for neointimal formation prevent neointimal formation. We used a T-channel selective blocker, NNC55-0396, to validate our hypothesis. We first determined the effect of NNC55-0369 on VSMC proliferation, and the results showed that NNC55-0369 was able to decrease the proliferation rate of rat VSMCs ( Figure 6A ). We also found that NNC55-0369 was able to decrease the platelet-derived growth factor induced [Ca 2+ ] i elevation in VMSCs (see Supplementary material online, Figure S4 ). We then tested the effect of NNC55-0396 in vivo. Neointimal formation was significantly reduced in NNC55-0396-treated mice compared with the saline controls ( Figure 6B) . Moreover, the I/M ratio was significantly decreased in the NNC55-0396-treated group compared with the saline-treated controls ( Figure 6C ). These results support the idea that a specific T-channel blocker could serve as an effective agent to prevent neointimal formation, thus reducing the severity of restenosis after artery intervention.
Discussion
In this study, we demonstrated that wire injury-induced neointimal formation was abolished in mice lacking Ca v 3. 41 Up-regulation of K V 3.4 and K V 1.3 has also been observed in proliferating human and rat smooth muscle cells, respectively. 42, 43 Selective blockade of K Ca 3.1 inhibited smooth muscle cell proliferation and reduced neointimal formation in a rat model. 44 Opening of these K + channels can lead to membrane hyperpolarization, and hyperpolarized resting membrane potentials would favour the opening of Ca v 3.1 T-channels in proliferating VSMCs. T-channels have been implicated in the regulation of cell-cycle progression and cell proliferation. 45 In rat aorta VSMCs, T-channels are mainly expressed in the G 1 and S phases but not in the G 0 phase. 13 Another study also showed that T-channels are predominantly expressed in the S phase in rat neonatal cardiac myocytes. 46 Previous studies have shown that CCBs are probably effective in reducing restenosis in clinical trials. 19 -21 Currently, most of the CCBs used are L-channel blockers, however, downregulation of L-channels is known to occur in proliferating VSMCs. 50, 51 It is known that many
CCBs not only block L-channels, but also block T-channels to a different extent. 23, 24 Therefore, it is likely that some effects of CCBs in reducing restenosis result from the blocking of T-channels. In this study, we used NNC55-0396, a CCB that irreversibly blocks calcium T-channels, 52, 53 to examine the reduction in neointimal formation in wild-type mice after vascular injury in vivo. Our results showed that infusion of NNC55-0396 for 7 days was effective in preventing neointimal formation in wild-type injured arteries. These results are consistent with our finding that Ca v 3.1 mRNA was upregulated 7 days after artery injury when there was no obvious neointimal formation. Our results provide a new insight into the regulatory mechanism of Ca v 3.1 in cell proliferation in VSMCs, and also demonstrate that Ca v 3.1-specific CCBs may be more beneficial than other inhibitors to prevent restenosis after PCI.
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